The grand challenge of nephrology

Frontiers in Medicine

Volumn 1, Issue SEP, 2014, Pages

  Trachtman, Howard ^a   Benzing, Thomas ^b   Sever, Sanja ^c   Harris, Raymond Clement ^d   Reiser, Jochen ^e  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

Author keywords

Basic science; Clinical setting; End stage kidney disease; Kidney; Nephrology

Indexed keywords

EID: 85007263599     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2014.00028     Document Type: Article

References (17)

1. Ritz E, Wiecek A. The kidney in the bible. Dtsch Med Wochenschr (2006) 131(51-52):2916-9. doi:10.1055/s-2006-957222
2. Merrill JP, Murray JE, Harrison JH, Guild WR. Landmark article Jan 28, 1956: successful homotransplantation of the human kidney between identical twins. By John P. Merrill, Joseph E. Murray, J. Hartwell Harrison, and Warren R. Guild. JAMA (1984) 251(19):2566-71. doi:10.1001/jama.251.19.2566
3. Parker MG, Ibrahim T, Shaffer R, Rosner MH, Molitoris BA. The future nephrology workforce: will there be one? Clin J Am Soc Nephrol (2011) 6(6):1501-6. doi:10.2215/CJN.01290211
4. Parker MG, Pivert KA, Ibrahim T, Molitoris BA. Recruiting the next generation of nephrologists. Adv Chronic Kidney Dis (2013) 20(4):326-35. doi:10.1053/j.ackd.2013.03.004
5. Al-Awqati Q. Basic research in nephrology: are we in decline? J Am Soc Nephrol (2012) 23(10):1611-6. doi:10.1681/ASN.2012060553
6. Samuels JA, Molony DA. Randomized controlled trials in nephrology: state of the evidence and critiquing the evidence. Adv Chronic Kidney Dis (2012) 19(1):40-6. doi:10.1053/j.ackd.2012.01.009
7. Bryan L, Ibrahim T, Zent R, Fischer MJ. The kidney research predicament. J Am Soc Nephrol (2014) 25(5):898-903. doi:10.1681/ASN.2013121313
8. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol (2004) 15(2):411-9. doi:10.1097/01.ASN.0000100125.21491.46
9. Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis (2014) 63(5):771-80. doi:10.1053/j.ajkd.2013.10.043
10. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 83(4):749-56. doi:10.1038/ki.2012.428
11. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol (2013) 33(1):14-22. doi:10.1016/j.semnephrol.2012.12.006
12. McMahon GM, Preis SR, Hwang SJ, Fox CS. Mid-adulthood risk factor profiles for CKD. J Am Soc Nephrol (2014). doi:10.1681/ASN.2013070750
13. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science (2010) 329(5993):841-5. doi:10.1126/science.1193032
14. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (2009) 361(1):11-21. doi:10.1056/NEJMoa0810457
15. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol (2008) 4(9):490-501. doi:10.1038/ncpneph0891
16. Rosenberg ME. Cell-based therapies in kidney disease. Kidney Int Suppl (2013) 3(4):364-7. doi:10.1038/kisup.2013.78
17. Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Annu Rev Med (2013) 64:357-66. doi:10.1146/annurev-med-050311-163340